Resveratrol supplementation improves functional performance in knee osteoarthritis by upregulating sirtuin 1: a randomized study

Karim A, Khan HA, Ahmad F, Qaisar R · Inflammopharmacology

The abstract reports reduced pain (VAS) and WOMAC scores and improved Oxford Knee Score, range of motion, gait velocity, grip strength and SPPB versus placebo, with higher plasma SIRT1 and lower 8-isoprostanes. Effect sizes are deliberately not restated: the full text is paywalled and could not be obtained for verification, so this record carries the abstract's directional claims only.

Population

Adults 63-73 with knee osteoarthritis, single center (Rehman Medical Institute, Peshawar, Pakistan)

Intervention

Resveratrol 500 mg once daily for 12 weeks

Comparator

Placebo

Limitations

Retrospectively registered (OSF, April 2025, after completion). One of three positive publications by the same Sharjah-Peshawar group within about a year, all single-center at 500 mg/day with overlapping outcome panels (also PMID 40990472, 16 weeks, n=123; PMID 41679011, 18 weeks, n=129); whether these are independent cohorts or overlapping enrolments cannot be determined from the papers. Plasma SIRT1 — an intracellular enzyme assayed in blood — is an endpoint of uncertain meaning for joint tissue. No trial registration preceded enrolment; full texts of all three are paywalled.